Pre-made Tovetumab benchmark antibody ( Whole mAb, anti-PDGFRA therapeutic antibody, Anti-CD140A/PDGFR-2/PDGFR2 Antibody) for drug discovery and mechanism of action (MOA) research

Pre-Made Tovetumab biosimilar, Whole mAb, Anti-PDGFRA Antibody: Anti-CD140A/PDGFR-2/PDGFR2 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Tovetumab is an anti-PDGFRa monoclonal antibody designed for the treatment of cancer. It was developed by MedImmune, and trialed for use in glioblastoma and non-small cell lung cancer. Development was discontinued in 2013.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-ab-590-1mg	1mg	3090
GMP-Bios-ab-590-10mg	10mg	Inquiry
GMP-Bios-ab-590-100mg	100mg	Inquiry
GMP-Bios-ab-590-xmg	＞100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Tovetumab biosimilar, Whole mAb, Anti-PDGFRA Antibody: Anti-CD140A/PDGFR-2/PDGFR2 therapeutic antibody
INN Name	Tovetumab
Target	PDGFRA
Format	Whole mAb
Derivation	Human
Species Reactivity	Human
CH1 Isotype	IgG2
VD LC	Kappa
Highest_Clin_Trial (Jan '20)	Phase-II
Est. Status	Discontinued
100% SI Structure	None
99% SI Structure	None
95-98% SI Structure	None
Year Proposed	2013
Year Recommended	2014
Companies	Cambridge Antibody Technology;MedImmune
Conditions Approved	na
Conditions Active	na
Conditions Discontinued	Glioblastoma;Non-small cell lung cancer;Solid tumours
Development Tech	na